Stockscreener 앱 받기
46.50
3.53%
-1.70
시간 외 거래:
46.50
Protagonist Therapeutics Inc 주식(PTGX)의 최신 뉴스
Winners and wishers: 9 potential Bay Area drug approvals coming this year - The Business Journals
(PTGX) Investment Analysis - news.stocktradersdaily.com
Wall Street Analysts See a 27.36% Upside in Protagonist Therapeutics (PTGX): Can the Stock Really Move This High? - Yahoo Finance
Protagonist Therapeutics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2025 - Bluefield Daily Telegraph
Why Protagonist Therapeutics, Inc. (PTGX) Went Up on Monday - MSN
Insider Sell: William Waddill Sells 4,000 Shares of Protagonist Therapeutics Inc (PTGX) - GuruFocus
Protagonist Therapeutics Takeda To Lead Regulatory Strategy For Rusfertide In Polycythemia Vera NDA - MarketScreener
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Protagonist Therapeutics, Inc. With Losses of $100,000 to Contact the Firm - Business Wire
Protagonist Therapeutics (PTGX) Upgraded to Buy: Here's Why - MSN
Protagonist Therapeutics director Waddill sells $217,000 in stock By Investing.com - Investing.com South Africa
Protagonist Therapeutics director Waddill sells $217,000 in stock - Investing.com
Analysts Mentions Growth Catalysts for Protagonist Therapeutics (PTGX) — Best Biotech Stock for 2025? - MSN
These 10 biotech companies are changing how we discover new drugs and treat complex diseases - Fast Company
Fast Company Ranks Protagonist Among Elite Biotech Innovators: 2 FDA Filings Coming - StockTitan
Is Protagonist Therapeutics, Inc. (PTGX) the Best Healthcare Stock For Long-Term Investment? - Insider Monkey
Protagonist Therapeutics CFO Ali Asif sells $1.46 million in stock By Investing.com - Investing.com South Africa
Protagonist Therapeutics’ chief medical officer sells $1.7 million in stock By Investing.com - Investing.com Canada
Protagonist Therapeutics CFO Ali Asif sells $1.46 million in stock - Investing.com India
Protagonist Therapeutics’ chief medical officer sells $1.7 million in stock - Investing.com
Protagonist Therapeutics (NASDAQ:PTGX) Price Target Raised to $76.00 - Defense World
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Purchased by Victory Capital Management Inc. - Defense World
Protagonist Therapeutics Unveils 'Paradigm-Shifting' Drug And Breaks Out - MSN
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Acquired by Bank of New York Mellon Corp - Defense World
Protagonist Therapeutics’ SWOT analysis: promising pipeline drives stock outlook By Investing.com - Investing.com South Africa
Protagonist Therapeutics’ SWOT analysis: promising pipeline drives stock outlook - Investing.com
Learn to Evaluate (PTGX) using the Charts - Stock Traders Daily
Protagonist Therapeutics (NASDAQ:PTGX) Price Target Raised to $72.00 at BMO Capital Markets - Defense World
Protagonist Therapeutics (NASDAQ:PTGX) Hits New 1-Year High on Analyst Upgrade - Defense World
Protagonist Therapeutics: Much More Than Rusfertide In Place To Carry It (NASDAQ:PTGX) - Seeking Alpha
Wedbush Adjusts Protagonist Therapeutics Price Target to $70 From $58, Maintains Outperform Rating - Marketscreener.com
Protagonist Therapeutics Soars as Icotrokinra Drives Breakthroug - GuruFocus.com
Protagonist Therapeutics price target raised to $76 from $60 at Truist - TipRanks
Protagonist Therapeutics Soars as Icotrokinra Drives Breakthrough Success - Yahoo Finance UK
Gilead Sciences To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Protagonist Therapeutics price target raised to $72 from $62 at BMO Capital - TipRanks
Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Shares Climb 44% But Its Business Is Yet to Catch Up - Simply Wall St
Protagonist Therapeutics price target raised to $80 from $54 at H.C. Wainwright - TipRanks
Protagonist Therapeutics Gets IBD Stock Rating Upgrade - Investor's Business Daily
10 Firms Buck Market Bloodbath on Monday - Insider Monkey
Protagonist Therapeutics’ (PTGX) Buy Rating Reaffirmed at HC Wainwright - Defense World
1.23%
1.63%
자본화:
|
볼륨(24시간):